Domainex and Pharmidex have announced the formation of a strategic alliance to provide an integrated drug-discovery-services platform.
The service offering will amalgamate Domainex's Leadbuilder technology for cost-effective hit finding and its medicinal-chemistry team with Pharmidex's expertise and in-vitro and in-vivo capabilities in drug metabolism and pharmacokinetics (DMPK).
The alliance will have a particular emphasis on tackling the most challenging of scientific problems, including novel or difficult drug targets.
Examples of this proficiency include Domainex's capabilities in peptidomimetic drugs and Pharmidex's in the study of DMPK within the central nervous system (Neuro PK and Neuro PD).
